{"product_id":"generic-drugs-market-by-therapeutic-application-cardiovascular-infectious-diseases-cancer-diabetes-others-by-route-of-administration-oral-injections-others-by-distribution-channel-hospital-pharmacies-retail-pharmacies-online-providers-glo","title":"Generic Drugs Market By Therapeutic Application (Cardiovascular, Infectious Diseases, Cancer, Diabetes, Others), By Route of Administration (Oral, Injections, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online providers): Glo","description":"\u003cp\u003eGeneric Drugs Market By Therapeutic Application (Cardiovascular, Infectious Diseases, Cancer, Diabetes, Others), By Route of Administration (Oral, Injections, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032\u003cbr\u003e\nThe Generic Drugs Market was valued for $385,320.00 million in 2022 and is estimated to reach $835,706.50 million by 2032, exhibiting a CAGR of 8.1% from 2023 to 2032.\u003c\/p\u003e\n\n\u003cp\u003eGeneric drugs is a medication similar to a branded drug,  which has previously been approved for marketing in terms of dose form, potency, mode of administration, quality, performance characteristics, and intended purpose. The generic drugs are available at lower prices as compared to branded drugs. \u003c\/p\u003e\n\n\u003cp\u003eThe growth of the generic drugs market is driven by surge in prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases. According to World Cancer Research Fund International (WCRF), there were an estimated 18.1 million cancer cases globally in 2020, of which 9.3 million cases were in men and 8.8 million in women. In addition, the affordable price of generic drugs and latest product approval and product launch contribute to the growth of the market. For instance, in February 2021, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.\u003c\/p\u003e\n\n\u003cp\u003eMoreover, the rise in cost of branded medication, high demand for generic medicines, and rise in awareness about generic drugs contribute to the growth of the market. In addition, prominent players in the global generic drugs market have adopted various strategies such as product launches, acquisition, and investments in R\u0026amp;D for advancement in generic drugs to strengthen their position in the market and sustain the competitive environment. \u003c\/p\u003e\n\n\u003cp\u003eMoreover, alarming increase in prevalence of diabetes, technological advancements in generic drugs, and rise in the geriatric population are some of the key factors driving the growth of the market. The geriatric population are more prone to chronic diseases such as diabetes and hypertension. However, concern related to the consistency and stability of generic drugs hamper the market growth. Conversely, increase in awareness of generic drugs among the population is expected to provide lucrative opportunities for the growth of the market in the near future. In addition, extensive R\u0026amp;D activities in the field of generic drugs along with significant improvement in medical infrastructure is anticipated to open new avenues for the expansion of the market during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eThe generic drugs market is segmented into therapeutic application, route of administration, distribution channel, and region. On the basis of therapeutic application, the market is divided into cardiovascular, infectious diseases, cancer, diabetes, and others. Based on the route of administration, the market is classified into oral, injection and others.\u003c\/p\u003e\n\n\u003cp\u003eDepending on distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online providers. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).\u003c\/p\u003e\n\n\u003cp\u003eMajor companies profiled in the report include Amneal Pharmaceuticals, Aurobindo Pharma, Cipla, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Sandoz International GmbH, Sun Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Viatris Inc.\u003c\/p\u003e\n\n\u003cp\u003eKey Benefits For Stakeholders\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the generic drugs market analysis from 2022 to 2032 to identify the prevailing generic drugs market opportunities.\u003cbr\u003e\nThe market research is offered along with information related to key drivers, restraints, and opportunities.\u003cbr\u003e\nPorter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.\u003cbr\u003e\nIn-depth analysis of the generic drugs market segmentation assists to determine the prevailing market opportunities.\u003cbr\u003e\nMajor countries in each region are mapped according to their revenue contribution to the global market.\u003cbr\u003e\nMarket player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.\u003cbr\u003e\nThe report includes the analysis of the regional as well as global generic drugs market trends, key players, market segments, application areas, and market growth strategies.\u003c\/p\u003e\n\n\u003cp\u003eKey Market Segments\u003c\/p\u003e\n\n\u003cp\u003eBy Distribution Channel\u003c\/p\u003e\n\n\u003cp\u003eHospital pharmacies\u003cbr\u003e\nRetail pharmacies\u003cbr\u003e\nOnline providers\u003c\/p\u003e\n\n\u003cp\u003eBy Therapeutic Application\u003c\/p\u003e\n\n\u003cp\u003eCardiovascular\u003cbr\u003e\nInfectious Diseases\u003cbr\u003e\nCancer\u003cbr\u003e\nDiabetes\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Route of Administration\u003c\/p\u003e\n\n\u003cp\u003eOral\u003cbr\u003e\nInjections\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe\u003cbr\u003e\nAsia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\nLAMEA\u003cbr\u003e\nBrazil\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of LAMEA\u003cbr\u003e\nKey Market Players\u003cbr\u003e\nAmneal Pharmaceuticals, Inc.\u003cbr\u003e\nAurobindo Pharma\u003cbr\u003e\nCipla Ltd\u003cbr\u003e\nGlaxoSmithKline plc\u003cbr\u003e\nHikma Pharmaceuticals PLC\u003cbr\u003e\nLupin\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nSun Pharmaceutical Industries Ltd\u003cbr\u003e\nTeva Pharmaceutical Industries Limited\u003cbr\u003e\nViatris Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease Note: It will take 7-10 business days to complete the report upon order confirmation.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 252 Pages \/ MCW16245470","offer_id":47662700331314,"sku":null,"price":4608.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/generic-drugs-market-by-therapeutic-application-cardiovascular-infectious-diseases-cancer-diabetes-others-by-route-of-administration-oral-injections-others-by-distribution-channel-hospital-pharmacies-retail-pharmacies-online-providers-glo","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}